Posted on 03 July 2009
Health-care giant J&J is making a $1 billion bet for a stake in Irish drug maker Elan and will invest an additional $500 million in Elan’s closely watched experimental bapineuzumab that is in late-stage studies to treat Alzheimer’s, the companies announced this morning.
With the deal, Elan essentially turns over to J&J the development rights of [...]
Popularity: 1% [?]
Posted on 03 July 2009
Can cost-effective health-care measures that have worked in poorer countries be applied to in the U.S.?
That’s the question the WSJ asks amid the debate over how the U.S. can reign in health-care costs. It’s become clear that many stakeholders in the debate are in favor of figuring out what treatments and tests are most effective [...]
Popularity: 1% [?]
Posted on 03 July 2009
The UN’s top health official has opened a forum in Mexico on combating swine flu by saying that the spread of the virus worldwide is now unstoppable.
World Health Organization head Margaret Chan added that the holding of the meeting in Cancun showed confidence in Mexico, which has been hard hit.
The WHO says most H1N1 cases [...]
Popularity: 1% [?]
Posted on 03 July 2009
Multaq, Sanofi-Aventis’s treatment for heart-rhythm disorders, has made a comeback. Rejected by the FDA in 2006 because of safety concerns, the agency has approved Multaq, the company announced today.
The drug approval is the French drug maker’s first major U.S. approval in seven years, according to Bloomberg. Late last year, Sanofi decided to discontinue development of [...]
Popularity: 1% [?]
Posted on 03 July 2009
Graceway Pharmaceuticals obtained commercialization rights to three dermatological molecules from Pfizer. The acquisition and license agreement includes related transferred or licensed intellectual properties.
This transaction is part of Pfizer’s plan to out-license noncore programs; the firm identified CNS diseases, oncology, and cardiovascular diseases as its focus. Pfizer continues to be responsible, however, for performing developmental and [...]
Popularity: 1% [?]
Business of Health
Posted on 04 March 2009
Pfizer will gain rights to 39 generic oral medicines in the US and 20 in Europe, with an additional 11 in France. The company will also acquire rights for 12 injectable antibiotics in the US and Europe, including penicillins and cephalosporins.
Popularity: unranked [?]
Drug Development
Posted on 02 July 2009
The FDA issued a complete response letter requesting additional manufacturing information regarding the regulatory filing for Novartis’ meningitis vaccine Menveo for use in people aged 11 to 55 years old, the drugmaker reported Wednesday. Novartis spokesperson Eric Althoff indicated that a decision on the application is now expected to be delayed to late 2009 or [...]
Popularity: 1% [?]
Neurological Disorders
Posted on 02 July 2009
Scientists have identified thousands of tiny genetic variations which together could account for more than a third of the inherited risk of schizophrenia.
They also showed the condition is genetically similar to bipolar disorder also known as manic depression.
The findings came from work by three separate teams, who analysed DNA from thousands of people.
The studies - [...]
Popularity: 1% [?]
News Wire
Posted on 03 July 2009
The UN’s top health official has opened a forum in Mexico on combating swine flu by saying that the spread of the virus worldwide is now unstoppable.
World Health Organization head Margaret Chan added that the holding of the meeting in Cancun showed confidence in Mexico, which has been hard hit.
The WHO says most H1N1 cases [...]
Popularity: 1% [?]
Pharmaceutical Industry
Posted on 03 July 2009
Can cost-effective health-care measures that have worked in poorer countries be applied to in the U.S.?
That’s the question the WSJ asks amid the debate over how the U.S. can reign in health-care costs. It’s become clear that many stakeholders in the debate are in favor of figuring out what treatments and tests are most effective [...]
Popularity: 1% [?]
